Prazosin
|
|
- CAS-Nr.
- 19216-56-9
- Bezeichnung:
- Prazosin
- Englisch Name:
- Prazosin
- Synonyma:
- pressin;PRAZOSIN;furazosin;minipress;AKOS B020009;PrazosinBase;Terazosin-010;Prazosin USP/EP/BP;ART-CHEM-BB B020009;Terazosin Impurity15
- CBNumber:
- CB8120869
- Summenformel:
- C19H21N5O4
- Molgewicht:
- 383.4
- MOL-Datei:
- 19216-56-9.mol
|
Prazosin Eigenschaften
- Schmelzpunkt:
- 278-280°C
- Siedepunkt:
- 510.33°C (rough estimate)
- Dichte
- 1.3275 (rough estimate)
- Brechungsindex
- 1.7600 (estimate)
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- pKa 6.54(50% EtOH) (Uncertain)
- Farbe
- White to Off-White
- Wasserl?slichkeit
- 3.2mg/L(22.5 ºC)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P264 |
Nach Gebrauch gründlich waschen. |
P264 |
Nach Gebrauch gründlich waschen. |
P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
P321 |
Besondere Behandlung |
P332+P313 |
Bei Hautreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
P362 |
Kontaminierte Kleidung ausziehen und vor erneutem Tragen waschen. |
|
Prazosin Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Prazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output.
Definition
ChEBI: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Clinical Use
Prazosin is effective in reducing all grades of hypertension.
The drug can be administered alone in mild
and (in some instances) moderate hypertension.When
the hypertension is moderate or severe, prazosin generally
is given in combination with a thiazide diuretic
and a -blocker. The antihypertensive actions of prazosin
are considerably potentiated by coadministration
of thiazides or other types of antihypertensive
drugs.
Prazosin may be particularly useful when patients
cannot tolerate other classes of antihypertensive drugs
or when blood pressure is not well controlled by other
drugs. Since prazosin does not significantly influence
blood uric acid or glucose levels, it can be used in hypertensive patients whose condition is complicated by
diabetes mellitus or gout.
Prazosin and other -antagonists find use in the
management of benign prostatic obstruction, especially
in patients who are not candidates for surgery. Blockade
of -adrenoceptors in the base of the bladder and in the
prostate apparently reduces the symptoms of obstruction
and the urinary urgency that occurs at night.
Nebenwirkungen
Although less of a problem than with phenoxybenzamine
or phentolamine, symptoms of postural hypotension,
such as dizziness and light-headedness, are the
most commonly reported side effects associated with
prazosin therapy. These effects occur most frequently
during initial treatment and when the dosage is sharply
increased. Postural hypotension seems to be more pronounced
during Na deficiency, as may occur in patients
on a low-salt diet or being treated with diuretics, -
blockers, or both.
Prazosin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Prazosin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 130)Lieferanten
19216-56-9(Prazosin)Verwandte Suche:
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-piperazin
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine.
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-piperazin
- (4-(4-AMino-6,7-diMethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)Methanone hydrochloride salt
- 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
- 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-quinazolin
- furazosin
- PRAZOSIN
- pressin
- PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(2-FURANYLCARBONYL)-
- minipress
- AKOS B020009
- 1-(4-amino-6,7-dimethoxy-2-quinazolinyl-4-(2-furanylcarbonyl)) piperrazine
- ART-CHEM-BB B020009
- PrazosinBase
- Prazosin Hcl 19237-84-4 / Base
- (2-Furanyl)[4-(4-amino-6,7-dimethoxyquinazoline-2-yl)piperazine-1-yl] ketone
- 1-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-4-(furan-2-ylcarbonyl)piperazine
- 2-[4-(2-Furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
- [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone
- [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-furan-2-ylmethanone
- [4-(4-azanyl-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-furan-2-yl-methanone
- 1-(4-aMino-6,7-diMethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hidrochloride
- Terazosin EP Impurity K
- Terazosin-010
- Terazosin Impurity15
- [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-methanone
- Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-
- Prazosin USP/EP/BP
- 2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
- Linagliptin Impurity CD10125
- 19216-56-9
- C19H21N5O4